cariprazine hydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
cariprazine hydrochloride: clinical details
Prescribing considerations
- Licensed for adult schizophrenia; safety and efficacy are not established below 18 years.
- Effects and adverse reactions can lag behind treatment changes because cariprazine and its active metabolites persist for weeks.
- Use caution with Parkinson’s disease, seizure risk, cardiovascular disease, QT-risk factors, stroke risk and venous-thromboembolism risk.
- Use in severe renal or hepatic impairment is not recommended; evidence in older adults is limited.
- Not recommended for elderly people with dementia-related psychosis.
Contraindications and cautions
- Hypersensitivity to cariprazine or an excipient.
- Concurrent strong CYP3A4 inhibitors.
- Concurrent strong or moderate CYP3A4 inducers.
Monitoring
- Mental state, treatment response and suicidality.
- Akathisia, parkinsonism, dystonia and tardive dyskinesia.
- Weight, blood glucose and metabolic risk.
- Blood pressure and cardiovascular symptoms; consider ECG assessment where QT or cardiac risk is present.
- Venous-thromboembolism risk factors.
- New visual symptoms, with ophthalmological assessment where indicated.
- Tolerability after relevant treatment or interaction changes.
Clinical pharmacology
Cariprazine is a dopamine D3/D2 and serotonin 5-HT1A partial agonist, with antagonism at 5-HT2B, 5-HT2A and H1 receptors. It is metabolised mainly by CYP3A4 to active metabolites; slow accumulation and elimination delay the full effect of changes.
Formulation and product differences
- The selected UK products are hard gelatin capsules with presentation-specific colours and markings.
- Some capsule presentations contain Allura red AC (E129), which may cause allergic reactions.
- Keep capsules in the outer carton to protect them from light.
cariprazine hydrochloride preparations and strengths
Capsule
Route: Oral
Strengths: 1.5 mg, 3 mg, 4.5 mg, 6 mg
cariprazine hydrochloride interactions
Cariprazine is mainly metabolised by CYP3A4. Ask a pharmacist or prescriber before starting or stopping medicines, supplements or herbal products.
Strong CYP3A4 inhibitors, including clarithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, ritonavir and cobicistat
Can markedly increase exposure; combined use is contraindicated.
Moderate CYP3A4 inhibitors, including erythromycin, fluconazole, diltiazem and verapamil
Can increase exposure for several weeks, requiring clinical review and closer monitoring.
Strong or moderate CYP3A4 inducers, including carbamazepine, phenytoin, phenobarbital, rifampicin, modafinil and St John’s wort
Can substantially reduce exposure; combined use is contraindicated.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.